Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

• ClinicalTrials.gov Identifier: NCT04666129
• Recruitment Status: Recruiting
• First Posted: December 14, 2020
• Last Update Posted: September 6, 2022
• Sponsor: Myovant Sciences GmbH
• Information provided by (Responsible Party): Myovant Sciences GmbH

Study Description

Brief Summary:

This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).

Condition or disease	Intervention/treatment	Phase
Metastatic Castration-Resistant Prostate Cancer; Metastatic Castration-Sensitive Prostate Cancer; Non-Metastatic Castration-Resistant Prostate Cancer	Drug: Relugolix; Drug: Abiraterone; Drug: Prednisone; Drug: Methylprednisolone; Drug: Apalutamide; Drug: Docetaxel	Phase 1

Detailed Description:

This is a three-part, open-label, parallel-cohort study to assess the safety and tolerability of relugolix as the ADT component in combination treatment with abiraterone acetate plus a corticosteroid in patients with mCSPC or mCRPC (Part 1), apalutamide in patients with mCSPC or nmCRPC (Part 2), or docetaxel with or without prednisone in patients with mCSPC or mCRPC (Part 3).

The study will consist of a 45-day screening period followed by a 12-week treatment period with one of the three combination treatments (Parts 1, 2, or 3). All participants are required to have been treated with standard-of-care leuprolide acetate or a GnRH receptor antagonist (such as degarelix) in combination with either abiraterone plus prednisone. Participants will be transitioned from standard-of-care leuprolide acetate or the GnRH receptor antagonist to relugolix; with relugolix treatment initiated the day the next dose of leuprolide acetate or the GnRH antagonist is scheduled for administration with the prior dosing regimen of abiraterone acetate plus a corticosteroid, apalutamide, or docetaxel with or without prednisone being continued.

In addition to evaluating the safety and tolerability of relugolix, the study will also provide safety data as participants transition from injectable leuprolide acetate or degarelix to treatment with relugolix as the androgen-deprivation component of the treatment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 72 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
• Actual Study Start Date: February 18, 2021
• Estimated Primary Completion Date: January 2023
• Estimated Study Completion Date: November 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part 1: Relugolix plus Abiraterone plus a Corticosteroid; Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.	Drug: Relugolix; (Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.; Other Names: MVT-601; TAK-385; T-1331285; RVT-601; Orgovyx; Drug: Abiraterone; Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.; Other Names: Zytiga; Yonsa; Drug: Prednisone; (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily. (Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.; Drug: Methylprednisolone; For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.; Other Name: Medrol
Experimental: Part 2: Relugolix plus Apalutamide; Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.	Drug: Relugolix; (Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.; Other Names: MVT-601; TAK-385; T-1331285; RVT-601; Orgovyx; Drug: Apalutamide; Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.; Other Name: Erleada
Experimental: Part 3: Relugolix plus Docetaxel with or without Prednisone; Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.	Drug: Relugolix; (Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.; Other Names: MVT-601; TAK-385; T-1331285; RVT-601; Orgovyx; Drug: Prednisone; (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily. (Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.; Drug: Docetaxel; Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.; Other Names: Docefrez; Taxotere

Outcome Measures

Primary Outcome Measures :

1. Incidence of Adverse Events [ Time Frame: Baseline through Week 13 ]
   Parts 1, 2, and 3

Secondary Outcome Measures :

1. Mean Testosterone Serum Concentrations at Baseline (Day 1), Week 5, and Week 13 [ Time Frame: Baseline (Day 1), Week 5, and Week 13 ]
   Parts 1 and 2
2. Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Week 5, and Week 13 [ Time Frame: Baseline (Day 1), Week 5, and Week 13 ]
   Parts 1 and 2
3. Relugolix Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 [ Time Frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 ]
   Part 2
4. Apalutamide and N-desmethyl Apalutamide Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 [ Time Frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 ]
   Part 2
5. Mean Testosterone Serum Concentrations at Baseline (Day 1), Mid-Treatment, and Week 13 [ Time Frame: Baseline (Day 1), Mid-Treatment, and Week 13 ]
   Part 3
6. Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13 [ Time Frame: Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13 ]
   Part 3
7. Relugolix Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel [ Time Frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel ]
   Part 3
8. Docetaxel Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel [ Time Frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel ]
   Part 3
9. Incidence of Adverse Events [ Time Frame: Up to 52 weeks ]
   Parts 1, 2, and 3

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

1. A diagnosis of adenocarcinoma of the prostate confirmed by histologic or cytologic evidence and with a documented medical history of either:

   • mCSPC (Parts 1, 2, and 3) defined as having at least two of three risk factors at the baseline (Day 1) visit:

     • Total Gleason score of ≥ 6; and
     • Presence of ≥ 2 metastatic lesions on bone scan; OR
     • Radiologic evidence of measurable visceral metastases with exception of hepatic metastases.
   • nmCRPC (Part 2 only) defined as disease progression despite maintaining castration levels of testosterone with androgen deprivation therapy (ADT), as evidenced by an increase in consecutive prostate-specific antigen (PSA) concentrations (2 measurements, at least one week apart).

   • mCRPC (Parts 1 and 3) defined as disease progression despite maintaining castration levels of testosterone with ADT:

     • An increase in consecutive PSA (2 measurements at least 1 weeks apart);
     • Worsening clinical symptoms;
     • Radiologic evidence demonstrating enlarged metastatic lesions or the development of new metastases.

2. Currently receiving standard-of-care treatment of leuprolide acetate (3-, 4-, or 6-month injections [intramuscular Lupron or subcutaneous Eligard]) or a gonadotropin-releasing hormone (GnRH) receptor antagonist (such as degarelix) in combination with:

   • Part 1: abiraterone acetate 1000 mg or fine-particle abiraterone acetate 500 mg once daily plus prednisone 5 mg once daily for participants with mCSPC or twice daily for participants with mCRPC or methylprednisolone 4 mg once daily and in whom abiraterone has been well tolerated (that is, without evidence of hepatotoxicity requiring dose adjustment for abiraterone).
   • Part 2: apalutamide 240 mg once daily and in whom apalutamide has been well tolerated (that is, without a fracture, fall, or seizure episode or need to dose adjust due to any adverse events).
   • Part 3: docetaxel 75 mg/m2 and in whom docetaxel has been well tolerated (that is, no evidence of hypersensitivity reaction, febrile neutropenia or neutrophils < 500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions, or moderate neurosensory signs and/or symptoms despite dose reduction).

Key Exclusion Criteria:

A patient will not be eligible for inclusion in the study if any of the following criteria apply:

1. A medical history of brain or hepatic metastases based on radiologic evidence or a medical history of surgical castration;
2. Received combination treatment with a GnRH analog or GnRH receptor antagonist with either abiraterone acetate plus a corticosteroid (Part 1) or apalutamide (Part 2) in patients with mCSPC (Part 1 and Part 2) or nmCRPC (Part 2) for a total duration > 24 months or in patients with mCRPC (Part 1) for a total duration > 6 months;
3. Is scheduled or anticipates being scheduled for major surgery during the study treatment period;

4. A current diagnosis of a malignancy other than prostate cancer, with the exception of any of the following:

   • Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of any type;
   • Adequately treated Stage I cancer that is currently in remission and has been in remission for ≥ 2 years;
   • Any other cancer from which the patient has been disease-free for ≥ 3 years;

5. Abnormal clinical laboratory test value(s) at the screening visit or prior to the baseline (Day 1) visit including:

   • Serum creatinine > 2.0 mg/dL;
   • Platelets < 100 × 103/μL;
   • Hemoglobin < 10.0 g/dL;
   • Leukocytes (WBC) < 3 × 103/μL;
   • Absolute neutrophil count < 1.5 × 103/μL;
   • Hemoglobin A1c (HbA1c) > 8%; Note (Part 3 only): Transfusions and/or administration of growth factors are permitted as indicated for the clinical management of docetaxel-related hematologic effects and in accordance with the investigator's judgement.
6. Known hepatic disease, including alcoholic liver disease or viral hepatitis such as hepatitis A (hepatitis A virus IgM positive), chronic hepatitis B (HbsAg positive), or chronic hepatitis C (HCV antibody positive, confirmed by HCV RNA) or clinical signs of hepatic disease such as jaundice;

7. A medical history within 6 months prior to the screening visit or a current diagnosis of any of the following:

   • Myocardial infarction;
   • Unstable angina;
   • Unstable symptomatic ischemic heart disease;
   • Congestive heart failure classified as NYHA class III or IV heart failure;
   • Thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular event[s]);
   • Any other significant cardiac condition (eg, pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease);
8. An abnormal ECG
9. Uncontrolled hypertension
10. Hypotension
11. Bradycardia
12. Positive HIV
13. Medical history of a bleeding disorder or current clinical evidence of gastrointestinal bleeding or active bleeding from another anatomical location.
14. A medical history within 1 year of the screening visit of drug or alcohol abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders V
15. Received an investigational drug within 28 days or 5 half-lives, whichever is longer, prior to the baseline (Day 1) visit;
16. Prior use of any prohibited medication(s) and restrictive medication(s) without the appropriate washout period or use of a prohibited medication during the study treatment period is planned;
17. A contraindication or known history of hypersensitivity to any of the study treatments or components thereof, or has a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates study participation;
18. Any other medical or psychiatric condition that, in the opinion of the investigator, would interfere with accomplishing the study objectives or the patient completing the study;
19. Is a study site employee or is a primary family member (spouse, parent, child, or sibling) of a site employee involved in the conduct of the study.

Contacts and Locations

Contacts

Contact: Clinical Trials at Myovant; 650-278-8743; ClinicalTrials@Myovant.com

Locations

United States, Arizona

Urological Associates of Southern Arizona, P.C.; Recruiting

Tucson, Arizona, United States, 85741

United States, Arkansas

Arkansas Urology; Recruiting

Little Rock, Arkansas, United States, 72211

United States, Colorado

Colorodo Clinical Research; Recruiting

Lakewood, Colorado, United States, 80228

United States, Maryland

Chesapeake Urology Research Associates; Completed

Baltimore, Maryland, United States, 21204

United States, Massachusetts

University of Massachusetts Medical School; Recruiting

Worcester, Massachusetts, United States, 01655

United States, New Jersey

New Jersey Urology; Recruiting

Saddle Brook, New Jersey, United States, 07663

New Jersey Urology; Not yet recruiting

Voorhees, New Jersey, United States, 08043

United States, New York

Clinical Research Alliance, Inc.; Recruiting

Westbury, New York, United States, 11590

United States, North Carolina

Alliance Urology; Recruiting

Greensboro, North Carolina, United States, 27403

Wake Forest Baptist Health; Recruiting

Winston-Salem, North Carolina, United States, 27157

United States, Ohio

Clinical Research Solutions; Recruiting

Middleburg Heights, Ohio, United States, 44130

United States, Pennsylvania

Center for Advanced Urology, LLP d/b/a: MidLantic Urology; Recruiting

Bala-Cynwyd, Pennsylvania, United States, 19004

Keystone Urology Specialists; Recruiting

Lancaster, Pennsylvania, United States, 17604

United States, South Carolina

Carolina Urologic Research Center; Recruiting

Myrtle Beach, South Carolina, United States, 29572

United States, Tennessee

Urology Associates, P.C.; Recruiting

Nashville, Tennessee, United States, 37209

United States, Texas

UT Southwestern Medical Center; Recruiting

Dallas, Texas, United States, 75390

Urology San Antonio; Recruiting

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Myovant Sciences GmbH

Investigators

• Study Director: Myovant Medical Monitor; Myovant Sciences

More Information

• Responsible Party: Myovant Sciences GmbH
• ClinicalTrials.gov Identifier: NCT04666129
• Other Study ID Numbers: MVT-601-049
• First Posted: December 14, 2020
• Last Update Posted: September 6, 2022
• Last Verified: September 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Myovant Sciences GmbH:

mCRPC; mCSPC; Relugolix; Abiraterone; Prednisone; Leuprolide acetate; nmCRPC; Apalutamide; Docetaxel; Degarelix; Methylprednisolone

Additional relevant MeSH terms:

Prostatic Neoplasms; Hypersensitivity; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Prostatic Diseases; Immune System Diseases; Prednisone; Methylprednisolone; Docetaxel; Relugolix; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Gastrointestinal Agents; Neuroprotective Agents; Protective Agents; Androgen Antagonists